AI News about drug regulation

Groundbreaking Developments in Health and Pharmaceutical Sector | Health

FDA Streamlines Biosimilar Testing, Slashing Drug Costs The FDA has introduced new guidelines to streamline biosimilar drug testing, dramatically reducing costs for vital biologic medications used in cancer treatment and other diseases. Despite biosimilars representing only 5% of prescriptions, they account for 51% of total drug expenditure. These regulatory changes aim to make life-saving treatments more accessible and affordable.